See more : Andean Precious Metals Corp. (APM.V) Income Statement Analysis – Financial Results
Complete financial analysis of ERYTECH Pharma S.A. (ERYP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ERYTECH Pharma S.A., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Giantplus Technology Co., Ltd. (8105.TW) Income Statement Analysis – Financial Results
- Aqua Power Systems Inc. (APSI) Income Statement Analysis – Financial Results
- Som Distilleries & Breweries Limited (SDBL.NS) Income Statement Analysis – Financial Results
- Sichuan Energy Investment Development Co., Ltd. (1713.HK) Income Statement Analysis – Financial Results
- SW Umwelttechnik Stoiser & Wolschner AG (SWUT.VI) Income Statement Analysis – Financial Results
ERYTECH Pharma S.A. (ERYP)
About ERYTECH Pharma S.A.
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 3.36M | 4.14M | 3.36M | 19.72M | 10.78M | 6.61M | 1.80M | 3.46M |
| Cost of Revenue | 0.00 | 0.00 | 57.58M | 52.19M | 33.47M | 25.46M | 19.72M | 10.78M | 6.61M | 5.33M | 3.46M |
| Gross Profit | 0.00 | 0.00 | -57.58M | -48.83M | -29.33M | -22.10M | 0.00 | 0.00 | 0.00 | -3.53M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | -1,451.52% | -708.80% | -656.90% | 0.00% | 0.00% | 0.00% | -195.63% | 0.00% |
| Research & Development | 19.91M | 45.10M | 57.58M | 52.19M | -19.72M | -25.46M | 0.00 | 0.00 | 0.00 | 2.50M | 0.00 |
| General & Administrative | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.89M | 15.10M | 14.97M | 17.16M | 14.60M | 8.52M | 6.66M | 7.62M | 4.36M | 3.55M | 3.30M |
| Other Expenses | -6.65M | -3.69M | -3.72M | -5.28M | -4.45M | -3.10M | -3.99M | -2.81M | -2.03M | -4.29M | -5.68M |
| Operating Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 10.15M | 5.43M | 2.67M | 4.81M | 2.34M | 1.76M | -2.39M |
| Cost & Expenses | 27.15M | 56.52M | 68.83M | 64.07M | 43.62M | 30.89M | 22.39M | 15.58M | 8.95M | 7.09M | 1.07M |
| Interest Income | 4.45M | 13.00K | 889.00K | 2.95M | 163.00K | 405.00K | 545.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.36M | 2.14M | 5.35M | 1.53M | 9.00K | 15.00K | 4.00K | 5.00K | 6.80K | 4.66K | 9.38K |
| Depreciation & Amortization | -19.90M | 9.06M | 889.00K | 2.95M | 797.00K | 532.00K | 425.00K | 288.00K | 276.52K | 180.30K | 292.09K |
| EBITDA | -22.69M | -47.46M | -67.94M | 5.28M | 4.45M | 3.36M | -21.47M | -14.72M | -8.60M | -8.00M | -1.86M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -1,817.09% | -904.20% | -980.56% | -108.90% | -136.63% | -130.00% | -443.87% | -53.83% |
| Operating Income | -2.80M | -56.52M | -68.83M | -64.07M | -43.62M | -30.89M | -22.39M | -15.58M | -8.95M | -7.09M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -1,904.70% | -1,054.16% | -918.22% | -113.55% | -144.61% | -135.32% | -393.13% | -31.04% |
| Total Other Income/Expenses | 3.09M | 2.72M | -4.47M | -67.94M | -42.67M | -2.64M | 488.00K | 567.00K | 68.17K | -1.10M | -1.09M |
| Income Before Tax | 293.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.90M | -15.02M | -8.88M | -8.18M | -2.16M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -1,862.66% | -923.68% | -996.82% | -111.07% | -139.35% | -134.29% | -454.14% | -62.54% |
| Income Tax Expense | 521.00K | 2.00K | 3.00K | -1.00K | 2.00K | -3.00K | 10.00K | -3.00K | -20.16K | -40.02K | 7.64K |
| Net Income | -228.00K | -53.80M | -73.30M | -62.66M | -38.22M | -33.53M | -21.91M | -15.01M | -8.86M | -8.14M | -2.17M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -1,862.63% | -923.73% | -996.73% | -111.13% | -139.32% | -133.98% | -451.92% | -62.77% |
| EPS | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| EPS Diluted | -0.01 | -2.27 | -3.99 | -3.49 | -2.13 | -1.87 | -2.74 | -2.16 | -1.51 | -1.74 | -0.39 |
| Weighted Avg Shares Out | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
| Weighted Avg Shares Out (Dil) | 31.02M | 23.69M | 18.39M | 17.94M | 17.94M | 17.94M | 7.98M | 6.96M | 5.87M | 4.69M | 5.54M |
ERYTECH Provides Business Update and Reports Financial Results for the Third Quarter of 2020
Conference call and webcast on Friday, November 6 at 2:30 pm CET/8:30 am ET
ERYTECH Announces Abstract with Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Selected for Oral Presentation at the American Society of Hematology 2020 Annual Meeting
LYON, France and CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announces that an abstract detailing...
Monthly information related to total number of voting rights and shares composing the share capital – October 31, 2020.
Article 223-16 of general regulation of French Autorité des Marchés Financiers
ERYTECH Secures €10 Million in Non-Dilutive Financing, Guaranteed by the French Government
LYON, France and CAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced today that it has received financing...
ERYTECH to Host Third Quarter 2020 Conference Call and Business Update on November 6, 2020
LYON, France, Oct. 29, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext Paris : ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells , t oday announced that it will...
ERYTECH Appoints Stewart Craig as Chief Technical Officer
LYON, France and CAMBRIDGE, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, announced the appoint ment of Dr. Stewart...
Erytech Pharma: Exploring New Ways To Battle Cancer
Erytech is a company with a promising novel method targeting the large cancer market with unmet needs.
Erytech Spikes On Fast Track, And Other News: The Good, Bad And Ugly Of Biopharma
Erytech spiked 37% after lead pancreatic cancer drug candidate fast tracked by the FDA. Pfizer is progressing with its Covid-19 treatment candidate. Bausch Heal
ERYTECH to Host First Quarter 2018 Conference Call and Business Update
LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP - Nasdaq: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will host its 2018 first quarter conference call...
ERYTECH Reports Top-line Results of Phase 2b Study of Eryaspase for the Treatment of AML
LYON, France--(BUSINESS WIRE)--Regulatory News: ERYTECH Pharma (Euronext Paris: ERYP) (Nasdaq: ERYP) ("ERYTECH"), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced topline results from its Phase 2b clinical study evaluating eryaspase...
Source: https://incomestatements.info
Category: Stock Reports